Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 2, 2002, Pages 87-92

  Gordon, Leo I ^a   Witzig, Thomas E ^a   Wiseman, Greg A ^a   Flinn, Ian W ^a   Spies, Stewart S ^a   Silverman, Daniel H ^a   Emmanuolides, Christos ^a   Cripe, Larry ^a   Saleh, Mansoor ^a   Czuczman, Myron S ^a   Olejnik, Teresa ^a   White, Christine A ^a   Grillo López, Antonio J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; TOSITUMOMAB I 131;

CANCER GRADING; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; DOSIMETRY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TARGETING; HUMAN; ISOTOPE LABELING; LONG TERM CARE; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIOIMMUNOTHERAPY;

EID: 0036180910     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30148     Document Type: Conference Paper

References (33)

1. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients
2. A revolution in the treatment of non-Hodgkin's lymphoma
3. Karnofsky lecture: Immunotherapy of lymphoma
4. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
5. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
6. Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro
7. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
8. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
9. Clinical applications of anti-CD20 antibodies
10. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein
11. Preclinical and phase I and II trials of rituximab
12. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma
13. Conventional treatments for non-Hodgkin's lymphoma: The need for new therapies
14. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia
15. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma
16. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma
17. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: Dosimetry and clinical implications
18. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy
19. Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation
20. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma
21. Radioimmunotherapy with iodine-131-I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
22. Radioimmunotherapy for lymphoma
23. Iodine-131-anti B1 radioimmunotherapy for B-cell lymphoma
24. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma
25. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
26. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: Outpatient iodine-131 anti-B1 therapy
27. Health physics consequences of out-patient treatment of non-Hodgkin's lymphoma with 131I-radiolabeled anti-B1 antibody
28. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
29. Randomized controlled trial of Zevalin radioimmunotherapy (RAIT) versus rituximab immunotherapy for patients with B-cell non-Hodgkin's lymphoma (NHL)
30. Phase I/II 90Y-zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
31. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue
32. Quality of life and treatment value in the management of hematologic malignancies
33. Zevalin (IDEC-Y2B8) radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma